
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Medable Inc. has announced a multi-company research framework to accelerate development of diagnostics and treatments for COVID-19. The ACCESS initiative-short for American COVID-19 Collaborative Enabling Seamless Science-provides a mobile consumer application and secure infrastructure to connect health researchers and clinical trial teams securely with up to millions of home-bound individuals in the United States. ACCESS is a collaborative effort led by Medable, together with technology, healthcare and life sciences companies including BioIntelliSense, Datavant, Parexel, PWNHealth, and the American Heart Association’s Center for Health Technology and Innovation.
For more information, click






